RENNIE SPEARMINT

Quốc gia: Israel

Ngôn ngữ: Tiếng Anh

Nguồn: Ministry of Health

Thành phần hoạt chất:

CALCIUM CARBONATE; MAGNESIUM CARBONATE

Sẵn có từ:

BAYER ISRAEL LTD

Mã ATC:

A02AC10

Dạng dược phẩm:

CHEWABLE TABLETS

Thành phần:

CALCIUM CARBONATE 680 MG; MAGNESIUM CARBONATE 80 MG

Tuyến hành chính:

PER OS

Loại thuốc theo toa:

Not required

Sản xuất bởi:

DELPHARM GAILLARD, FRANCE

Khu trị liệu:

COMBINATIONS

Chỉ dẫn điều trị:

Relief of hyperacidity and heartburn.

Ngày ủy quyền:

2021-02-07

Tờ rơi thông tin

PATIENT LEAFLET IN ACCORDANCE WITH THE PHARMACISTS' REGULATIONS
(PREPARATIONS) - 1986
This medicine is dispensed without a doctor's prescription
RENNIE
® SPEARMINT
CHEWABLE TABLETS
ACTIVE INGREDIENTS:
Every chewable tablet contains:
Calcium carbonate 680 mg (equivalent to 272 mg calcium)
Magnesium carbonate (heavy) 80 mg
INACTIVE INGREDIENTS AND ALLERGENS: see section 2 under "Important
information about some of
this medicine’s ingredients" and section 6 "Additional information".
READ THE ENTIRE LEAFLET CAREFULLY BEFORE YOU START USING THIS
MEDICINE. This leaflet contains
concise information about this medicine. If you have any further
questions, consult your doctor or
pharmacist.
Take the medicine according to the instructions in the section about
dose in this leaflet. Consult
your pharmacist if you need further information. Contact a doctor if
your symptoms of illness get
worse or do not improve after 14 days.
1.
WHAT IS THE MEDICINE INTENDED FOR?
This medicine is intended for the relief of gastric hyperacidity and
heartburn.
THERAPEUTIC GROUP: antacid.
Rennie is used for treatment of symptoms resulting from reflux of
acidic gastric content to the
oesophagus and mouth, causing a sensation of burning or pain behind
the sternum.
Rennie is also used for treatment of symptoms caused by hyperacidity
of gastric content, e.g. in
case of heartburn. Rennie can also be used for the treatment of
symptoms caused by an ulcer in
the upper digestive tract.
2.
BEFORE USING THE MEDICINE
DO NOT USE THE MEDICINE IF:
•
you are sensitive (allergic) to calcium carbonate or to magnesium
carbonate or to any of the
additional ingredients contained in the medicine (for the list of the
inactive ingredients, see
section 6
"Additional information").
•
you suffer from a severe kidney dysfunction or kidney stones.
•
you suffer from high calcium levels or low phosphate levels in the
blood.
SPECIAL WARNINGS ABOUT USING THIS MEDICINE
BEFORE STARTING TREATMENT WITH THE MEDICINE, TELL YOUR DOCTOR IF:
•
you suffer from sarcoidosis (an i

Đặc tính sản phẩm

1.
NAME OF THE MEDICINAL PRODUCT
Rennie Spearmint, chewable tablets
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Per chewable tablet 680 mg calcium carbonate and 80 mg magnesium
carbonate.
Excipients: each chewable tablet contains 400 mg sorbitol.
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Chewable tablets.
Rennie Spearmint is a creamy white, square tablet with rounded edges
and the inscription
“RENNIE” embossed on both sides; the tablet has a spearmint aroma.
4.
CLINICAL PARTICULARS
4.1 THERAPEUTIC INDICATIONS
Relief of hyperacidity and heartburn.
4.2 POSOLOGY AND METHOD OF ADMINISTRATION
POSOLOGY
For adults and children over the age of 12 years:
1-2 Rennie Spearmint chewable tablets at a time, as needed, preferably
to be taken about
one hour after a meal and before going to bed. For the treatment of
heartburn, an
additional 1 -2 tablets may be taken between those times. The maximum
daily dose of 10
tablets must not be exceeded. The patient must be advised to consult a
doctor if
symptoms persist for longer than 14 days.
It is advisable to wait roughly 1 -2 hours between taking other
medicines and taking
Rennie.
Paediatric patients:
Only for use by adults and children over the age of 12 years.
The safety and efficacy in
children aged under 12 years have not yet been established.
Method of administration:For oral use. The tablets can be chewed or
sucked. The tablets
can be taken without water.
As with all antacids, if symptoms persist, diagnostic measures are
recommended to rule
out serious diseases.
For special warnings and precautions for use, see section 4.4.
4.3 CONTRAINDICATIONS
-
Hypersensitivity to any of the active substances or to any of the
excipients listed in
section 6.1.
-
Severe renal impairment, hypercalcaemia and/or conditions resulting in
hypercalcaemia.
-
Pre-existing hypophosphataemia.
-
Nephrolithiasis due to calculi containing calcium.
4.4
SPECIAL WARNINGS AND PRECAUTIONS FOR USE
Prolonged use should be avoided.
If the symptoms persist or only partially disappe